VTCN1 and triple-negative breast carcinoma: Similarly, the application of anti-B7H4/IL-15 bispecific antibodies against cold cancers like triple-negative breast cancers and ovarian cancer turned to improve immunogenicity within TME by enhancing the proliferation of CD8 T cells and boosting immune cell-mediated killing (ADCC) of B7H4+ tumour cells [154].